← Leaderboards
Yanming Du
Drexel University
$3,452,099
Attributed
$5,376,297
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,376,297 · 6
By mechanism
R01$2,886,297 · 1
R42$1,000,000 · 1
R41$900,000 · 2
R21$440,000 · 1
R43$150,000 · 1
Top collaborators
- Ju-Tao Guo6 shared
- Stephan Menne6 shared
Most similar at Drexel University
Same institution · by research overlap
- Srinivas Somarowthu$1,436,150
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadIn VivoPharmaceutical PreparationsHepatocyteSafetyIn VitroHepatitis B VirusHepatitis BCytotoxicityVirus ReplicationResistanceDesignChronic Hepatitis BLiverAcidsMetabolismDoseToxic EffectComplexAntiviral AgentsAbsorptionDrug KineticsAnimal ModelImmune
Grant awards (13)
Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$1,000,000
R42 · FY2025 · AI · contact PI
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$300,000
R41 · FY2024 · AI · contact PI
Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity$200,000
R21 · FY2024 · AI · contact PI
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$300,000
R41 · FY2023 · AI · contact PI
Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity$240,000
R21 · FY2023 · AI · contact PI
Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction$300,000
R41 · FY2022 · AI · contact PI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$537,218
R01 · FY2018 · AI
Advancing selective pyrazinyl aminothiazole derivatives for the treatment of primary liver cancer$150,000
R43 · FY2018 · CA · contact PI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$511,927
R01 · FY2017 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$578,621
R01 · FY2016 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$669,728
R01 · FY2015 · AI
Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$405,835
R01 · FY2014 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$182,968
R01 · FY2014 · AI